These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30827933)

  • 61. [Clinical Characteristics of 219 Patients with Primary Gastrointestinal Non-Hodgkin's Lymphoma].
    Li YY; Hu DZ; Wang YF; Zhao ZG; Cao Z; Zhang YZ; Zhang HL; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):849-854. PubMed ID: 32552946
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract][Full Text] [Related]  

  • 63. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
    Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients.
    Jiang S; Qin Y; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Zhang C; Zhou L; Sun Y; Shi Y
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e11-e16. PubMed ID: 31264371
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes.
    Bao C; Gu J; Huang X; You L; Zhou Z; Jin J
    Cytokine; 2023 Sep; 169():156289. PubMed ID: 37453327
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
    Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
    Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
    Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
    Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic Significance of Absolute Lymphocyte Count, Absolute Monocyte Count, and Absolute Lymphocyte Count to Absolute Monocyte Count Ratio in Follicular Non-Hodgkin Lymphoma.
    Mohsen A; Taalab M; Abousamra N; Mabed M
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e606-e615. PubMed ID: 32303487
    [TBL] [Abstract][Full Text] [Related]  

  • 69. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
    Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
    Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A dynamic predictive nomogram of long-term survival in primary gastric lymphoma: a retrospective study.
    Yang J; Liu T; Zhu Y; Zhang F; Zhai M; Zhang D; Zhao L; Jin M; Lin Z; Zhang T; Zhang L; Yu D
    BMC Gastroenterol; 2022 Jul; 22(1):347. PubMed ID: 35842604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A nomogram prognostic model for diffuse large B-cell lymphoma based on SUVmax and GNRI in elderly patients.
    Li M; Lu H; Fan J; Dai M; Su C
    EJHaem; 2023 Nov; 4(4):1030-1041. PubMed ID: 38024603
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study.
    Wang HK; Wei Q; Yang YL; Lu TY; Yan Y; Wang F
    Cancer Cell Int; 2023 Jan; 23(1):13. PubMed ID: 36707809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-Hodgkin's lymphomas: immunologic prognostic studies.
    Hadzi-Pecova L; Petrusevska G; Stojanovic A
    Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma.
    Zhu Y; Xu W; Zheng X; Zheng Z
    J Investig Med; 2019 Feb; 67(2):331-337. PubMed ID: 30258027
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma.
    Toji T; Takata K; Sato Y; Miyata-Takata T; Hayashi E; Habara T; Maeda Y; Tanimoto M; Yoshino T
    J Clin Pathol; 2015 Aug; 68(8):622-7. PubMed ID: 25935549
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
    Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
    Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China.
    Li X; Chen Y; Sun A; Wang Y; Liu Y; Lei H
    BMC Med Inform Decis Mak; 2023 Jul; 23(1):125. PubMed ID: 37460979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.